Cargando…

Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial non-small cell lung cancer (NSCLC). However, these patients often develop brain metastasis (BM) during their disease course. The major...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Kuan-Hung, Hong, Shu-Ting, Wang, Hsiang-Tsui, Lo, Yu-Li, Lin, Anya Maan-Yuh, Yang, James Chih-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187798/
https://www.ncbi.nlm.nih.gov/pubmed/27916828
http://dx.doi.org/10.3390/ijms17121998
_version_ 1782486900376862720
author Lin, Kuan-Hung
Hong, Shu-Ting
Wang, Hsiang-Tsui
Lo, Yu-Li
Lin, Anya Maan-Yuh
Yang, James Chih-Hsin
author_facet Lin, Kuan-Hung
Hong, Shu-Ting
Wang, Hsiang-Tsui
Lo, Yu-Li
Lin, Anya Maan-Yuh
Yang, James Chih-Hsin
author_sort Lin, Kuan-Hung
collection PubMed
description Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial non-small cell lung cancer (NSCLC). However, these patients often develop brain metastasis (BM) during their disease course. The major obstacle to treat BM is the limited penetration of anticancer drugs across the blood–brain barrier (BBB). In the present study, we utilized gefitinib-loaded liposomes with different modifications to improve gefitinib delivery across the in vitro BBB model of bEnd.3 cells. Gefitinib was encapsulated in small unilamellar liposomes modified with glutathione (GSH) and Tween 80 (SUV-G+T; one ligand plus one surfactant) or RF (SUV-RF; one α-helical cell-penetrating peptide). GSH, Tween 80, and RF were tested by the sulforhodamine B (SRB) assay to find their non-cytotoxic concentrations on bEnd.3 cells. The enhancement on gefitinib across the BBB was evaluated by cytotoxicity assay on human lung adenocarcinoma PC9 cells under the bEnd.3 cells grown on the transwell inserts. Our findings showed that gefitinib incorporated in SUV-G+T or SUV-RF across the bEnd.3 cells significantly reduced the viability of PC9 cells more than that of free gefitinib. Furthermore, SUV-RF showed no cytotoxicity on bEnd.3 cells and did not affect the transendothelial electrical resistance (TEER) and transendothelial permeability of sodium fluorescein across the BBB model. Moreover, flow cytometry and confocal laser scanning microscopy were employed to evaluate the endocytosis pathways of SUV-RF. The results indicated that the uptake into bEnd.3 cells was mainly through adsorptive-mediated mechanism via electrostatic interaction and partially through clathrin-mediated endocytosis. In conclusion, cell penetrating peptide-conjugated SUV-RF shed light on improving drug transport across the BBB via modulating the transcytosis pathway(s).
format Online
Article
Text
id pubmed-5187798
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-51877982016-12-30 Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80 Lin, Kuan-Hung Hong, Shu-Ting Wang, Hsiang-Tsui Lo, Yu-Li Lin, Anya Maan-Yuh Yang, James Chih-Hsin Int J Mol Sci Article Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial non-small cell lung cancer (NSCLC). However, these patients often develop brain metastasis (BM) during their disease course. The major obstacle to treat BM is the limited penetration of anticancer drugs across the blood–brain barrier (BBB). In the present study, we utilized gefitinib-loaded liposomes with different modifications to improve gefitinib delivery across the in vitro BBB model of bEnd.3 cells. Gefitinib was encapsulated in small unilamellar liposomes modified with glutathione (GSH) and Tween 80 (SUV-G+T; one ligand plus one surfactant) or RF (SUV-RF; one α-helical cell-penetrating peptide). GSH, Tween 80, and RF were tested by the sulforhodamine B (SRB) assay to find their non-cytotoxic concentrations on bEnd.3 cells. The enhancement on gefitinib across the BBB was evaluated by cytotoxicity assay on human lung adenocarcinoma PC9 cells under the bEnd.3 cells grown on the transwell inserts. Our findings showed that gefitinib incorporated in SUV-G+T or SUV-RF across the bEnd.3 cells significantly reduced the viability of PC9 cells more than that of free gefitinib. Furthermore, SUV-RF showed no cytotoxicity on bEnd.3 cells and did not affect the transendothelial electrical resistance (TEER) and transendothelial permeability of sodium fluorescein across the BBB model. Moreover, flow cytometry and confocal laser scanning microscopy were employed to evaluate the endocytosis pathways of SUV-RF. The results indicated that the uptake into bEnd.3 cells was mainly through adsorptive-mediated mechanism via electrostatic interaction and partially through clathrin-mediated endocytosis. In conclusion, cell penetrating peptide-conjugated SUV-RF shed light on improving drug transport across the BBB via modulating the transcytosis pathway(s). MDPI 2016-11-29 /pmc/articles/PMC5187798/ /pubmed/27916828 http://dx.doi.org/10.3390/ijms17121998 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lin, Kuan-Hung
Hong, Shu-Ting
Wang, Hsiang-Tsui
Lo, Yu-Li
Lin, Anya Maan-Yuh
Yang, James Chih-Hsin
Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80
title Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80
title_full Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80
title_fullStr Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80
title_full_unstemmed Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80
title_short Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80
title_sort enhancing anticancer effect of gefitinib across the blood–brain barrier model using liposomes modified with one α-helical cell-penetrating peptide or glutathione and tween 80
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187798/
https://www.ncbi.nlm.nih.gov/pubmed/27916828
http://dx.doi.org/10.3390/ijms17121998
work_keys_str_mv AT linkuanhung enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80
AT hongshuting enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80
AT wanghsiangtsui enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80
AT loyuli enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80
AT linanyamaanyuh enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80
AT yangjameschihhsin enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80